cAMP Hunter™ GCGR Bioassay Kit
The cAMP Hunter™ GCGR Bioassay Kit is an easy-to-use cell based assay to measure drug potency and detect neutralizing antibodies. This bioassay assesses ligand (e.g. Glucagon) based activation of GCGR receptor activity via detection of levels of intracellular cAMP.
Catalog #: 95-0042Y2-00213
Size:
2-Plate
Unit Price: USD 1,989.00
Log in to see your actual price
Qty
Overview
Specifications
Documentation
Resources
Related Info
Biological Background
The Glucagon Receptor (GCGR), also known as glucagon-binding protein or GL-R, is a GPCR regulating glucose metabolism. Activated by glucagon, GCGR triggers gluconeogenesis and glycogenolysis, crucial for glucose homeostasis. It plays a vital role in metabolic disorders like obesity and type 2 diabetes.
GCGR signals through cAMP and β-arrestin pathways. The cAMP cascade promotes glucose release during fasting, while β-arrestin regulates receptor desensitization. Dysregulation of these pathways leads to insulin resistance, excess glucose, and lipid metabolism issues, making GCGR a key obesity research target.
Eurofins DiscoverX's cAMP Hunter™ GCGR Bioassay Kit provides a reliable cell-based assay to measure drug potency and detect neutralizing antibodies. From characterization to QC lot-release, it ensures GCGR-targeting compounds' quality and supports drug discovery for metabolic diseases.
Product Highlights
- Designed for glucagon receptor (GCGR, GL-R) signaling analysis
- Detects intracellular cAMP levels as a response to GCGR activation
- Ready-to-use, cell-based assay format
- Suitable for drug discovery, potency assessment, and neutralizing antibody detection
- Applicable across various stages, including characterization and QC lot-release
cAMP Hunter GCGR Bioassay Kit Assay Principle
In the cAMP Hunter GCGR Bioassay Kit, CHO-K1 cells overexpressing glucagon receptor (GCGR) utilize the natural coupling status of the GPCR to Gαs to monitor activation of the receptor. When GCGR is activated by glucagon, it stimulates adenylate cyclase, which in turn enables the production of cAMP. The resulting increase in cellular cAMP levels is measured using a homogenous, gain-of-signal competitive immunoassay based on Enzyme Fragment Complementation (EFC) technology.
The signal from the assay is directly proportional to the amount of cellular cAMP in the well, i.e., the higher the GCGR activation, the greater the cellular cAMP levels, and the larger the signal produced in the assay.
